Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

given to CVD patients in combination with statins. ApoA-I therapy has the potential to reduce the overall cost of cardiovascular disease, which is estimated in the U.S. at US $475 billion annually, by 5% to 16%.

Resverlogix is also pleased to announce that it will host a live teleconference today, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to discuss the top line results of this clinical trial. The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast is posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix090928.html. The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 ... zur Erfassung biologischer Daten in Verbindung mit ... patentiert. Das LBS nimmt gleichzeitig mehrere Blutproben ... Patienten und sucht erhöhte biologische Aktivitäten in ... die Entdeckung und Entwicklung neuer Medikamente und ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, announced ... has developed an issue brief titled, “What is the ... Workgroup, a part of WEDI’s Strategic National HPID Implementation ... Medicaid Services (CMS) to identify common misuse of the ...
(Date:7/28/2014)... CA and Annapolis Junction, MD (PRWEB) July 28, 2014 ... and research leader in personalized medicine, will be exhibiting ... services at this year’s International Spine Intervention Society’s ... take place July 30th-August 3rd, at the Hyatt Regency, ... designed to enhance the knowledge and clinical competence of ...
(Date:7/28/2014)... July 28, 2014 ... Identification Market by Products (Consumables, Instruments, Services), Methods (Phenotypic, ... User (Detection, Characterization) - Global Forecasts to ... Market is estimated at $896.5 Million in ... Million by 2019, growing at a CAGR ...
Breaking Biology Technology:PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3
... introduces a,new accessory, MPX(TM) (Multiplex) Blotting System, for ... can be incorporated into a,variety of assays including ... transduction pathway analysis, or any,other common Western blotting ... 7 x 8.5 cm., Processing is as ...
... Cardium Therapeutics,(Amex: CXM ) and ... that,InnerCool has entered into a exclusive commercialization ... distributor of medical products.,N.G.C. Medical primarily sells ... interventional cardiology markets. They also provide,in-service management ...
... REDWOOD CITY, Calif., June 19 Cardica, Inc.,(Nasdaq: ... Ph.D., the,company,s president and chief executive officer, is scheduled ... Thursday, June 26, 2008,at 12:30 p.m. Eastern Time. The ... To access the live and subsequently archived webcast ...
Cached Biology Technology:LI-COR(R) Biosciences Introduces New Tools for High Throughput Western Blotting 2Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 6
(Date:7/28/2014)... He calls himself the bug hunter, but the target ... be found and identified with special methods and instruments. ... State Veterinary Diagnostic Laboratory at Kansas State University, recently ... enterovirus G, which is an important find in the ... cells, but didn,t know what it was," Hause said. ...
(Date:7/28/2014)... (July 28, 2014)The Brain & Behavior Research Foundation ... and Freedman Prizes, recognizing exceptional clinical and basic ... by NARSAD Young Investigator Grants. The grants enable ... neurobiological and psychosocial research for the prevention, early ... affect one in four people. , Six young ...
(Date:7/28/2014)... and treat HIV infection has been problematic until now ... arouse as they get rid of the invaders. Now, ... and the National Institutes of Health (NIH) have demonstrated ... around the time of infection could have long-term ... appeared in Nature . , Interferons, named ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Interfering with interferon 2
... common type of lung cancer are notoriously insensitive to ... cellular pathways that regulate responses to cisplatin have now ... the journal Cell Reports . The findings reveal ... how these patients will respond to chemotherapy, as well ...
... July 26, 2012 Administering high-doses of interleukin-2 (IL-2) has ... metastatic melanoma. An article published in the current ... peer-reviewed journal from Mary Ann Liebert, Inc. ( http://www.liebertpub.com ... the most effective. The article is available free ...
... July 26, 2012 Congenital hypothyroidism is thyroid hormone ... to neurocognitive impairments in infants and children. Although ... daily during pregnancy for normal fetal thyroid hormone production ... 1,100 g to be the safe upper limit for ...
Cached Biology News:New biomarker for common lung cancer predicts responses to chemotherapy 2Study associates excess maternal iodine supplementation with congenital hypothyroidism in newborns 2